Top Hedge Funds Recruit Medical Experts, Seeking New Opportunities Amid Stock Market Volatility with $200 Billion in Assets

According to Reuters, eight sources have revealed that the world’s top hedge funds are actively recruiting medical professionals, including doctors, scientists, and analysts, to provide in-depth expert analysis on the future trends of pharmaceutical stocks following significant volatility. As pharmaceutical companies release financial results and update their drug research progress, the stock market has experienced dramatic fluctuations this year.

For instance, on November 11, AbbVie announced that its mid-stage trial for a schizophrenia drug had failed, causing its stock to drop 11% at the open. Meanwhile, competitor Bristol-Myers Squibb saw its stock rise nearly 13% in pre-market trading. Similarly, Novo Nordisk, a large European publicly traded company, reported its third-quarter results in November, which included better-than-expected sales of its blockbuster weight-loss drug, causing its stock to surge over 7% in a single day.

Hedge funds, known for gaining an edge in technology or research-driven market trends, are closely monitoring this trend. According to two insiders, some of the largest multi-strategy hedge funds have begun recruiting doctors and medical scientists globally and across Europe in the past six months.

These funds include Balyasny, D.E. Shaw, Point72, Schonfeld, Qube, and Squarepoint, which collectively manage over $200 billion in assets. None of these funds have commented on this matter. Additionally, a recruiter and two investors have indicated that hedge funds are looking to hire these experts in their departments to provide deep insights into company growth prospects, including those early-stage drugs that may receive regulatory approval.

Due to confidentiality, all sources spoke anonymously. Multi-strategy hedge funds are among the largest in the industry, pursuing diverse investment strategies. Some funds operate with an independent team structure known as "pods," where researchers work as part of teams led by portfolio managers. Other funds employ a more collaborative structure, hiring analysts with scientific and medical backgrounds as resident experts.

Two sources familiar with hedge fund operations noted that in the past, hedge funds have hired scientists with expertise in geology or engineering to guide commodity trading. Large power companies also regularly hire meteorological engineers and meteorologists to monitor weather fluctuations, providing information for electricity market trading.

With the overall cost of borrowing in the economy decreasing, pharmaceutical R&D spending is expected to rise. Freddie Stacy, co-founder of Sheridan Executive, stated that the prospect of lower interest rates has led multi-strategy hedge funds to increase their hiring in the healthcare sector, particularly in Europe, which is unprecedented. He added that this trend has spread to Europe over the past six months and has intensified with advancements in artificial intelligence's role in pharmaceutical discovery and connection.

Recent analysis by Reuters shows that the volatility of European companies' earnings reports this year is approaching historical highs, rising nearly one-fifth from eight years ago. Experts point out that multi-strategy hedge funds are one of the driving factors behind this phenomenon. Data from hedge fund research firm PivotalPath shows that as of the end of October, these funds achieved an 8.5% return in 2024, surpassing the 7.6% return of the entire industry during the same period.

From a cultural perspective, doctors may align well with hedge funds. Mr. Stacy noted that former doctors are attractive because they can handle the extreme pressure encountered daily in the medical industry, making them naturally capable of coping with the volatility of trading floors. Hedge funds need individuals who possess courage and determination—and perhaps a bit of humility.